Trials / Completed
CompletedNCT00365300
Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Treatment-Withdrawal Study of the Efficacy and Safety of Pantoprazole Sodium Enteric-Coated Granules in Infants (1 Through 11 Months) With Symptomatic GERD.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 129 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 28 Days – 11 Months
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy of pantoprazole for the treatment of infants with symptomatic Gastroesophageal Reflux Disease (GERD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pantoprazole | |
| DRUG | Placebo |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2007-11-01
- Completion
- 2007-11-01
- First posted
- 2006-08-17
- Last updated
- 2010-05-04
- Results posted
- 2010-01-07
Locations
38 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00365300. Inclusion in this directory is not an endorsement.